Skip to main content
. 2001 Jan;45(1):129–137. doi: 10.1128/AAC.45.1.129-137.2001

FIG. 6.

FIG. 6

In vivo bioluminescence monitoring of EC14(pCGLS1.UC) in the neutropenic-mouse thigh model of infection using the ICCD camera. Each data point is the mean ± SE of the same four animals at each time point. Viable counts are indicated for 0- and 12-h time points for both the untreated infection control group and the ceftazidime treated group. IC, infection control; CAZ, ceftazidime treatment (50 mg/kg at 1 and 5 h postinfection).

HHS Vulnerability Disclosure